269 results about "Clinical value" patented technology

The invention relates to the field of bio-materials, and especially relates to an acellular matrix repairing gel and a new method for preparing the same. The invention discloses the acellular matrix repairing gel and the method for preparing the same, wherein the method includes steps of acellular treatment and gelatinization treatment on tissue and organs from mammal animals to prepare the acellular matrix repairing gel. The acellular matrix repairing gel is eliminated in immunogenicity of heterologous and foreign tissue, so that activity of extracellular matrix components of the tissue is maintained as more as possible. The gel can specially repair damaged tissue and organs of human body, is strong in applicability, is suitable for requirements of various irregular-shaped repair zones and different position environments in body and has a huge clinical value.

The invention described herein solves the challenges encountered in searching for clinical and genomic information from multiple data sources. Systems, methods, and devices of the invention allow a user to search a number of dissimilar information sources simultaneously, and view, process, and perform correlations on the information. The invention uses faceted search to process clinical values, genomic data, subject characteristics, and population characteristics, thereby providing a user with an array of information useful for monitoring or improving the state of health of a subject or a subject population. The invention allows a user to evaluate clinical and research information in a subject-centric way, and analyze information at either the individual or the population level.

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

A method for electronically resolving a discrepancy arising in a clinical data management system is provided. The discrepancy is converted, using a conversion map, from a back-end format, used to store a clinical value corresponding to the discrepancy, into a front-end format that is compatible with a front-end study definition. The discrepancy is then transferred, while in the front-end format, to a front-end site where the clinical value associated with the discrepancy was first entered. A discrepancy response is received from the front-end site. When the discrepancy response resolves the discrepancy, the discrepancy response is stored in the clinical data management system, thereby resolving the discrepancy.

The invention disclosed herewith is a computer-implemented method for evaluating the toxicity of chemical compounds. In particular, some embodiments of the invention comprise importing microarray data representing measurements of the RNA transcription from hepatocytes, and running at least one algorithm (such as a coefficient penalized linear regression algorithm) on the imported data to assess potential adverse drug effects. After the evaluation has been carried out, the results are exported to reports or databases.

In some embodiments of the invention, the algorithm has been trained on reference data using machine learning techniques.

In some embodiments of the invention, the evaluation of toxicity is carried out concurrently with the evaluation of efficacy, where it can be used to assess the clinical value of the compounds evaluated.

In some embodiments of the invention, the evaluation of toxicity is inserted into a pharmaceutical evaluation process prior to expensive testing of toxicity in animals.

The invention discloses a virtual medical expert based on a medical record database. The virtual medical expert comprises a medical data input device, a private statement similarity computing module, a diagnosis experience similarity computing module, a medical image similarity computing module, a comprehensive similarity computing module as well as a diagnosis and treatment scheme generation module, wherein the private statement similarity computing module, the diagnosis experience similarity computing module and the medical image similarity computing module are respectively used for computing indexes of the private statement similarity, examination result similarity and medical image similarity between a patient to be diagnosed and treated as well as diagnosed and treated patients recorded in the medical record database; the comprehensive similarity computing module is used for integrating the indexes of the private statement similarity, examination result similarity and medical image similarity with expert scoring-based clinical judgment importance indexes of the private statements of the patients, the examination results and the medical images, thereby computing the comprehensive similarity between the patient to be diagnosed and treated as well as the diagnosed and treated patients recorded in the medical record database; the diagnosis and treatment scheme generation module is used for selecting the highest-comprehensive-similarity medical record from all medical records of the diagnosed and treated patients in the medical record database, and outputting a corresponding diagnosis and treatment scheme. Through adoption of the virtual medical expert, the clinical values of electrical medical record information can be sufficiently exerted, and diagnosis and treatment suggestions can be offered to doctors or users.

The invention provides a stable liquid medicinal composition. The liquid medicinal composition contains therapeutically effective amount or diagnostically effective amount of artemisia pollen allergen, buffering effective amount of buffer solution with pH of 5.0 to 7.0, and pharmaceutically acceptable carrier. The form of the liquid medicinal composition is preferable oral liquid, injection, sublingual buccal tablets, aerosol, nasal agent or skin pricking agent. The invention also provides a method for preparing the liquid medicinal composition. The liquid medicinal composition provided by the invention can be used for treating or diagnosing various allergic diseases caused by artemisia pollen, and has broad application prospect and clinical value in the field of allergic disease diagnosis and treatment.

The invention relates to a portable active electroencephalogram monitor and a control method thereof, belonging to the field of medical apparatus and instruments. The electroencephalogram monitor comprises an electroencephalogram signal acquisition unit, an electroencephalogram signal analysis and storage unit and an upper computer, wherein an input and output end of the electroencephalogram signal acquisition unit is connected with a first input and output end of the electroencephalogram signal analysis and storage unit, and a first digital signal input and output end of the electroencephalogram signal analysis and storage unit is connected with an input and output end of the upper computer. The portable active electroencephalogram monitor has high stability and reliability and can be used for realizing the active long-term monitoring of accidental, transient, paroxysmal or characteristic electroencephalogram activities, and the normal life, study and work of patients can not be influenced. Because long-time electroencephalogram data can be continuously recorded, the electroencephalogram monitor has important clinic value in diagnosing epilepsia and cerebrovascular diseases and studying and analyzing sleep.

The invention discloses an ultrasonic coupling agent and application of the ultrasonic coupling agent in ultrasonic inspection or auxiliary treatment of clinical cavity canals, mucous membranes, non-intact skin and the like in hospital. The ultrasonic coupling agent consists of the following raw materials: safe and nontoxic silver ions or nanometer silver serving as a disinfectant, and bio-compatibility macromolecular materials serving as a viscosity regulator, an anti-discoloration agent, an anti-precipitant agent, and an anti-stimulant agent. The ultrasonic coupling agent meets the requirements on ultrasonic impedance and no corrosion, has the characteristics of disinfection, sterilization, safety, nontoxicity, no stimulation and the like, can effectively avoid cross infection in ultrasonic clinics, can be suitable for detecting the cavity canals, the mucous membranes and the non-intact skin, and has high medical clinical value. The ultrasonic coupling agent has a simple preparation method, and low cost of raw materials.

The invention discloses a DNA (Deoxyribonucleic Acid) library for detecting cholestatic jaundice pathogenic genes by virtue of a high-throughput sequencing technology and application thereof and in particular relates to a super-multiplet PCR primer which can cover the exon and adjacent areas of the genes according to 60 cholestatic jaundice pathogenic genes. The genome DNA of the sample is subjected to super-multiplet PCR amplification, the amplification product is sequenced by utilizing the high-throughput sequencing technology, the pathogenic mutation is searched, the genetic etiology of the cholestatic jaundice is clear, and a theoretical basis of genetics and molecular biology is provided for clinical diagnosis. The DNA library has the characteristics of accuracy, flexibility, rapidness and low cost. Moreover, according to the detection area of 60 genes, 15 common cholestatic genetic defects can be detected, and the DNA library has significance and clinical values on differential diagnosis of the cholestatic jaundice.

The invention discloses a method for forming an aortic stent graft. The method comprises the following steps: acquiring an image of aorta, and extracting a three-dimensional (3D) model of the aorta according to the image; extracting diameter characteristics of the aorta in the axial direction of the aorta of the 3D model; reconstructing an aortic vascular model according to the extracted diameter characteristics; 3D-printing a water-soluble vascular inner core according to the aortic vascular model; dip-coating a polymer film on a surface of the water-soluble vascular inner core; spirally weaving a metal mesh outside the treated water-soluble vascular inner core as a metal stent; bonding the polymer film and the metal stent, and then removing the water-soluble vascular inner core to obtain the aortic stent graft. The method provided by the invention can efficiently and accurately manufacture a vascular stent graft according to the actual size of a thoracic descending aorta of a patient based on a 3D printing technology, can effectively solve a detect that an existing equal-diameter vascular stent does not match a true vascular size of the patient, provides an effective medical means for treatment of acute vascular aneurysm, and has important clinical value.

The invention relates to a fluorescence PCR (polymerase chain reaction) detection method for diagnosing infection of Chlamydia trachomatis (CT), neisseria gonorrhoeae (NG) and ureaplasma urealyticum (UU), which belongs to the field of nucleic acid in vitro diagnosis. The method comprises a polymerase chain reaction (PCR) system based on fluorescence PCR technology, contains a forward primer and areverse primer aiming at the CT/the NG/the UU and a fluorescent probe, and can detects DNA of three pathogens such as the CT, the NG, the UU and the like simultaneously in a reaction tub under suitable PCR condition. The method can diagnosing the infection of the CT/the NG/the UU in a clinical sample simply, conveniently and rapidly, has high sensitivity and specificity, and has important clinical value to early control and prevention of relevant genitourinary tract infections, blocking of an infection sources, and infection reduction of related pathogen.

The invention relates to a main artery non-invasive continuous blood pressure measuring method. The method comprises the following steps: emitting a first ultrasonic beam and a second ultrasonic beam to a region of a main artery blood vessel to be measured and collecting an echo signal; extracting shear wave from the echo signal and calculating the feature value of the shear wave spread along the wall of the main artery blood vessel; calculating the transient elasticity modulus of the wall of the main artery blood vessel according to the feature value; obtaining the continuous variation waveform of the diameter of the main artery blood vessel or the cross section area of the main artery blood vessel according to the echo signal; calculating the continuous variation waveform of the blood pressure of the main artery according to the transient elasticity modulus of the wall of the main artery blood vessel and the continuous variation waveform of the diameter of the main artery blood vessel or the cross section area of the main artery blood vessel; and calculating the continuous blood pressure waveform of the main artery. The main artery non-invasive continuous blood pressure measuring method can be applied to measurement of the blood pressure of main arteries such as carotid artery and achieves an important clinical value. In addition, the invention also provides a main artery non-invasive continuous blood pressure measuring device.

The invention discloses a deoxyribonucleic acid (DNA) library for detecting disease causing genes of aoreic dissection diseases through a targeted high-flux semiconductor sequencing technology and application thereof. In particular, a primer pond is designed according to 33 disease-causing genes of aoreic dissection diseases, a sample genome DNA is subjected to super-multiple polymerase chain reaction (PCR) amplification, and amplification products are sequenced by using the high-flux semiconductor sequence technology in order to find disease-causing mutation and lay theoretical bases on the aspects of genetics and molecular biology for clinical diagnosis. The DNA library has the advantages of accuracy, rapidness, flexibility and low cost. Through 33 gene detection areas, various common aoreic dissection relevant diseases such as familial aortic aneurysms or dissections (FTAAD), Marfan syndrome (MFS), Ehlers-Danlos syndrome (EDS), Loeys-Dietz syndrome (LDS) and aortic torsion syndrome (ATS) can be detected. The DNA library has important significance and a clinical value to diagnosis and identification of the aoreic dissections.

The invention provides a hydrogel near infrared light drug controlled-release system based on black phosphorus, wherein the system includes an agarose hydrogel carrier, and a black phosphorus nano thin piece and an anticancer drug which are loaded in the agarose hydrogel carrier. The hydrogel near infrared light drug controlled-release system based on black phosphorus has near infrared light response, can realize the change of a gelation state to a sol state through near infrared light irradiation in a body, can locally controllably release the drug and effectively kills tumor cells in lesionlocations; the drug release system has the controllable degradation characteristics and has extremely high clinical value in treatment of cancer. The invention also provides a preparation method of the hydrogel near infrared light drug controlled-release system based on black phosphorus.

The invention discloses a DNA library for detection of hereditary cardiomyopathy causing gene mutation through the targeting high-flux semiconductor sequencing technology and application thereof. Specifically, a primer pool is designed according to 80 hereditary cardiomyopathy causing genes, super-multiple PCR amplification is performed on sample genome DNA, and an amplified product is sequenced through the high-flux semiconductor sequencing technology to find pathogenic mutation so as to provide genetic and molecular biological theoretical bases for clinical diagnosis. The DNA library has the advantages of being accurate, quick, flexible and low in cost; through 80 gene detection areas related to the DNA library, five kinds of common hereditary cardiomyopathy including hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy and left ventricular myocardial densification incomplete cardiomyopathy can be detected, and the DNA library has an important meaning and clinical value for diagnosis and differential diagnosis of the hereditary cardiomyopathy.

The invention relates to a graphene catheter composition, a catheter preparation method and an application. The graphene catheter composition comprises the following components by the mass percentages: 90-99.5% of a biodegradable material, and 0.5-10% of graphene. The graphene catheter comprises a catheter and a biological adhesion substance layer, and the biological adhesion substance layer is arranged on the inner wall of the catheter; the catheter is prepared by the graphene catheter composition. The preparation method comprises that the graphene catheter composition is printed in 3D or electrospun to produce a catheter; the interior of the catheter is sprayed with a biological adhesion substance by 3D printing or electrospinning, and the catheter is crosslinked and solidified, so thatthe graphene catheter can be obtained. The catheter can promote regeneration, proliferation and differentiation of nerves, blood vessels and the like. In-vivo experiments show that the repair of animal peripheral nerves such as sciatic nerves is superior to that of autologous nerve transplantation, and practical and clinical value is achieved.

The invention discloses a combined diagnosis marker for predicting small hepatocellular carcinoma relapse. Based on an LASSO Cox regression model, the inventor confirms and establishes a small hepatocellular carcinoma relapse prediction model based on 6 gene signatures (including CD147, IL-7, Ki67, MIF, P97 and PD-L1) through analyzing a large number of cases; the risk ratio, defined by a 6 gene signature classifier, of a high relapse risk crowd to a low relapse risk crowd is 2.721 (95% CI: 1.633-4.532; P is smaller than 0.0001); the analysis of an internal validation group and an external validation group has the same result. The experiment proves that the classifier based on the 6 gene signatures can effectively predict different relapse risks of patients suffering from small hepatocellular carcinoma, the traditional diagnosis accuracy rate, predicted through clinicopathological parameters, of small hepatocellular carcinoma relapse is increased, the relapse risk of AFP-negative patients suffering from small hepatocellular carcinoma can be well judged, and the combined diagnosis marker has potential clinical value in the individualized treatment of small hepatocellular carcinoma.

The invention provides a black phosphorus-based hydrogel near-infrared immune drug controlled-release system. The system comprises an agarose hydrogel carrier as well as black phosphorus nanosheets and anti-cancer immune drugs carried in the agarose hydrogel carrier. The black phosphorus-based hydrogel near-infrared immune drug controlled-release system has near-infrared response, and can realize transformation from a gel state to a sol state through near-infrared light irradiation, so that locally controllable drug release can be achieved, and tumor cells in focus positions can be effectively killed; the system has a controllable degradation characteristic, and has extremely high clinical value for cancer treatment. The invention also provides a preparation method of the black phosphorus-based hydrogel near-infrared immune drug controlled-release system.

The invention belongs to the department of otolaryngology-head and neck and field of washing and therapeutic apparatus for nasal cavity, which aims at recovering the physiological function of nasal mucosa cilium system. The washing and therapeutic apparatus for nasal cavity comprises a forming system of bionic massage washing stream with adjustable pressure and an intelligent constant temperature system; the core of the main body is controlled by an 892051 single chip microcomputer which also carries out digital control for the temperature of washing stream and for the frequency as well as pressure of the bionic massage washing stream, while the flow rate is controlled and regulated manually. The constant temperature ranges between 35 and 42 DEG C; the frequency of the bionic massage washing stream ranges from 15 to 25 times per second; the pressure of water columns is regulated between 10 and 15 cmH2O(0.98 to 1.47KPa); and the regulation range of the flow rate is fixed between 70 and 100ml per minute. A liquid medicine container and an insulated heating container with heat transfer are combined to be a 'dual-container structure' so as to avoid electric leakage and denaturation and going-bad of the washing liquid medicine after being heated directly. The positive-pressure bionic massage washing stream from the washing and therapeutic apparatus can effectively recover the physiological function of nasal mucosa cilium system and realize the therapy of nasal diseases, thus having wide potential application and high clinical value.

The invention provides sealant hydrogel, a kit and a preparation method of the sealant hydrogel. The preparation method of the sealant hydrogel is simple. On the basis of common two-component hydrogel, a chemically modified polyethylene glycol macromonomer is added, and during use, the hydrogel with certain adhesive force is rapidly produced in situ after mixing. The produced hydrogel has good biocompatibility, bioadhesion, biodegradability and adjustable degradation performance, gelation time of the hydrogel is greatly shortened, important indexes such as gel content, swelling rate and the like are substantially increased, and degradation speed can be adjusted according to needs of application occasions. The sealant hydrogel can have important clinical value in the medical field, especially when used as a surgical sealant.

The invention discloses a DNA library for detecting pathogenic genes of multiple genetic vascular diseases through a targeted high-throughput semiconductor sequencing technology and application thereof. The operating method specifically comprises the following steps: designing a primer pool according to 151 pathogenic genes of genetic vascular diseases, performing super-multiple PCR amplification on genomic DNA of samples, sequencing the amplification products by utilizing the high-throughput semiconductor sequencing technology, searching pathogenic mutations, and providing genetic and molecular biological theoretical basis for clinical diagnosis. The DNA library disclosed by the invention has the characteristics of accuracy, rapidness, flexibility and low cost, the 151 gene detection areas involved in the invention are capable of detecting multiple genetic vascular diseases such as aortic dissection, arterial aneurysm, hemorrhagic apoplexy and the like, and the DNA library has great significance and clinical values on diagnosis and differential diagnosis of the genetic vascular diseases.